Background: Pulmonary vein isolation (PVI) is an accepted strategy for paroxysmal atrial fibrillation (PAF) and persistent AF (PerAF) ablation. Limited data are available on outcomes of cryoballoon (CB) PVI in patients with structural heart disease (SHD). The purpose is to assess the clinical efficacy of a single CB-PVI procedure in patients with PAF or PerAF who also have SHD. Methods: From April 2012, 460 AF patients with concomitant SHD underwent CB-PVI and were followed prospectively in the framework of the 1STOP ClinicalService ® project. Data on procedural outcomes and long-term freedom from AF recurrence were evaluated. Out of 460 subjects, 282 patients (61%) had PAF and 178 (39%) PerAF. Results: SHD patients were predominantly male (80.9%), old (62.8 ± 8.9 years), with preserved functional capacity (New York Heart Association class >1: 39.4%), high cardioembolic risk (CHA 2 DS 2 VASc score ≥2: 69.3%), and conserved left ventricular ejection fraction (56.5 ± 8% LVEF). Both subjects with PAF and PerAF had similar baseline clinical characteristics except for left atrial diameter (43.8 ± 7 vs. 45.7 ± 7 mm) and area (22.9 ± 5.2 vs. 25.1 ± 4.4 cm 2 ), respectively. Procedure time and fluoroscopic time as well as the rate of procedural complications were not different between subjects with PAF and PerAF. After a mean follow-up of 12 months, antiarrhythmic drug therapy had dropped from 71.7% before ablation to 33.6% post-ablation (p < 0.001) and the freedom from symptomatic AF recurrence was 78% for PAF and 77% for PerAF (p = 0.793). Furthermore, atrial arrhythmia recurrence rate was not related to SHD. Conclusions: In a large multicenter, real-world cohort, CB-PVI was used to treat patients with PAF and PerAF who also had SHD. The arrhythmia recurrence after a single procedure was not related to either the degree of cardiac structural remodeling or the type of AF, and the rate of AF recurrence was lower than previously reported in patients with SHD in other cohort series using focal radiofrequency catheter ablation.

Cryoablation for paroxysmal and persistent AF in patients with structural heart disease and preserved ejection fraction: Clinical outcomes from 1STOP, a multicenter observational project / G.B. Perego, S. Iacopino, G. Molon, G. Arena, R. Verlato, P. Pieragnoli, A. Curnis, G. Allocca, D. Nicolis, L. Sciarra, D. Catanzariti, G. Senatore, G. Rovaris, F. Brasca, C. Tondo. - In: JOURNAL OF CARDIOLOGY. - ISSN 0914-5087. - 74:1(2019), pp. 19-26. [10.1016/j.jjcc.2019.02.015]

Cryoablation for paroxysmal and persistent AF in patients with structural heart disease and preserved ejection fraction: Clinical outcomes from 1STOP, a multicenter observational project

G.B. Perego;F. Brasca;C. Tondo
2019

Abstract

Background: Pulmonary vein isolation (PVI) is an accepted strategy for paroxysmal atrial fibrillation (PAF) and persistent AF (PerAF) ablation. Limited data are available on outcomes of cryoballoon (CB) PVI in patients with structural heart disease (SHD). The purpose is to assess the clinical efficacy of a single CB-PVI procedure in patients with PAF or PerAF who also have SHD. Methods: From April 2012, 460 AF patients with concomitant SHD underwent CB-PVI and were followed prospectively in the framework of the 1STOP ClinicalService ® project. Data on procedural outcomes and long-term freedom from AF recurrence were evaluated. Out of 460 subjects, 282 patients (61%) had PAF and 178 (39%) PerAF. Results: SHD patients were predominantly male (80.9%), old (62.8 ± 8.9 years), with preserved functional capacity (New York Heart Association class >1: 39.4%), high cardioembolic risk (CHA 2 DS 2 VASc score ≥2: 69.3%), and conserved left ventricular ejection fraction (56.5 ± 8% LVEF). Both subjects with PAF and PerAF had similar baseline clinical characteristics except for left atrial diameter (43.8 ± 7 vs. 45.7 ± 7 mm) and area (22.9 ± 5.2 vs. 25.1 ± 4.4 cm 2 ), respectively. Procedure time and fluoroscopic time as well as the rate of procedural complications were not different between subjects with PAF and PerAF. After a mean follow-up of 12 months, antiarrhythmic drug therapy had dropped from 71.7% before ablation to 33.6% post-ablation (p < 0.001) and the freedom from symptomatic AF recurrence was 78% for PAF and 77% for PerAF (p = 0.793). Furthermore, atrial arrhythmia recurrence rate was not related to SHD. Conclusions: In a large multicenter, real-world cohort, CB-PVI was used to treat patients with PAF and PerAF who also had SHD. The arrhythmia recurrence after a single procedure was not related to either the degree of cardiac structural remodeling or the type of AF, and the rate of AF recurrence was lower than previously reported in patients with SHD in other cohort series using focal radiofrequency catheter ablation.
1STOP; Atrial fibrillation; Cryoballoon ablation; Paroxysmal atrial fibrillation; Persistent atrial fibrillation; Pulmonary vein isolation; Structural heart disease
Settore MED/11 - Malattie dell'Apparato Cardiovascolare
Article (author)
File in questo prodotto:
File Dimensione Formato  
Cryoablation for paroxysmal.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 634.57 kB
Formato Adobe PDF
634.57 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/643696
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact